"id:ID","description","uuid","label","text","instanceType","id","name"
"758","Main objective","1cc97a08-aeef-4dff-9d7b-34eaa665a8e8","","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","OBJECTIVE","Objective_1","OBJ1"
"759","Safety","50cb465b-9c6e-4233-b3d2-46ce70e98196","","To document the safety profile of the xanomeline TTS.","OBJECTIVE","Objective_2","OBJ2"
"760","Behaviour","66b454bc-06a5-40c9-a6e0-212d1af65f22","","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","OBJECTIVE","Objective_3","OBJ3"
